Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

36
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
36
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

516
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
516
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

67
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
67
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

539
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
539
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

451
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
451
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

57
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
57
  1. Home
  2. Research Domains
  3. Economics
  4. Applied Economics
  5. Experimental Economics
  6. Fda Expands Empagliflozin Heart Failure Indication

FDA Expands Empagliflozin Heart Failure Indication

Howard D Larkin

    JAMA
    |April 5, 2022

    Related Experiment Videos

    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
    03:42

    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

    Published on: March 29, 2024

    1.7K
    Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
    05:08

    Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

    Published on: October 3, 2019

    11.3K
    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
    07:05

    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

    Published on: February 23, 2024

    3.4K
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
    03:42

    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

    Published on: March 29, 2024

    1.7K
    Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
    05:08

    Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

    Published on: October 3, 2019

    11.3K
    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
    07:05

    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

    Published on: February 23, 2024

    3.4K